Gene · 3802
Papers2,190
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,190
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immune checkpoints HLA-E:CD94-NKG2A and HLA-C:KIR2DL1 complementarily shield circulating tumor cells from NK-mediated immune surveillance. | Cell Discov | 2024 | 38336855 | PubTator, text mining | PubMed |
| Obtaining Gene-Modified HLA-E-Expressing Feeder Cells for Stimulation of Natural Killer Cells. | Pharmaceutics | 2024 | 38276503 | PubTator, text mining | PubMed |
| MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides. | Nat Commun | 2024 | 38272918 | PubTator, text mining | PubMed |
| Activating KIR/HLA-I combinations as a risk factor of adult B-ALL. | Hum Immunol | 2024 | 38262874 | PubTator, text mining | PubMed |
| The role of exhausted natural killer cells in the immunopathogenesis and treatment of leukemia. | Cell Commun Signal | 2024 | 38254135 | PubTator, text mining | PubMed |
High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor. | J Exp Clin Cancer Res | 2024 | 38245792 | PubTator, text mining | PubMed |
KIR2DS1 and KIR2DL1-C245 Dominantly Repress NK Cell Degranulation Triggered by Monoclonal or Bispecific Antibodies, whereas Education by Uptuning Inhibitory Killer Ig-related Receptors Exerts No Advantage in Ab-dependent Cellular Cytotoxicity. | J Immunol | 2024 | 38240527 | PubTator, text mining | PubMed |
| Immune landscape and heterogeneity of cervical squamous cell carcinoma and adenocarcinoma. | Aging (Albany NY) | 2024 | 38206304 | PubTator, text mining | PubMed |
| Association of KIR Genes with Middle East Respiratory Syndrome Coronavirus Infection in South Koreans. | J Clin Med | 2024 | 38202265 | PubTator, text mining | PubMed |
| Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab. | Sci Rep | 2024 | 38185735 | PubTator, text mining | PubMed |
| High-resolution characterization of KIR genes polymorphism in healthy subjects from the Bulgarian population-A pilot study. | HLA | 2024 | 38180282 | PubTator, text mining | PubMed |
| A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemia. | medRxiv | 2024 | 37961528 | PubTator, text mining | PubMed |
| Cell State of Origin Impacts Development of Distinct Endometriosis-Related Ovarian Carcinoma Histotypes. | Cancer Res | 2024 | 37874327 | PubTator, text mining | PubMed |
| Impact of HLA Class I Antigen, Killer Inhibitory Receptor, and FCGR3A Genotypes on Breast Cancer Susceptibility and Tumor Stage. | Curr Mol Med | 2024 | 37461339 | PubTator, text mining | PubMed |
| Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics. | Front Immunol | 2023 | 38299154 | PubTator, text mining | PubMed |
| Current status and future perspective of natural killer cell therapy for cancer. | Med Rev (2021) | 2023 | 38235405 | PubTator, text mining | PubMed |
| The Combination of Bioavailable Concentrations of Curcumin and Resveratrol Shapes Immune Responses While Retaining the Ability to Reduce Cancer Cell Survival. | Int J Mol Sci | 2023 | 38203402 | PubTator, text mining | PubMed |
| Immunological Aspects of Infertility-The Role of KIR Receptors and HLA-C Antigen. | Cells | 2023 | 38201263 | PubTator, text mining | PubMed |
| The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy. | Front Immunol | 2023 | 38162657 | PubTator, text mining | PubMed |
| Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a "Trojan Horse". | Int J Mol Sci | 2023 | 38139149 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3802/papers?page=4